Former Arsanis CEO René Russo Tapped to Lead Akrevia Therapeutics

Xconomy Boston — 

René Russo has been appointed CEO of Akrevia Therapeutics. She is also joining the Cambridge, MA, company’s board of directors. Russo was most recently CEO of Arsanis (NASDAQ: ASNS), a biotech that combined operations with X4 Pharmaceuticals in a reverse merger earlier this year. Launched last year with $30 million in financing, Akrevia is developing cancer immunotherapies intended to hit tumors in a more targeted way.